COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.67
−0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.3M | 4.6M | — | — | — |
| Gross Profit | (2.3M) | (4.6M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 289.5M | 269.8M | 232.7M | 173.8M | 121.6M |
| SG&A Expense | 98.4M | 63.6M | 43.3M | 34.4M | 26.2M |
| General & Admin Expense | 98.4M | 63.6M | 43.3M | 34.4M | 26.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.2M) | (4.6M) | — | — | — |
| Total Operating Expenses | 386.8M | 328.7M | 275.9M | 208.1M | 147.8M |
| Cost and Expenses | 389.1M | 333.4M | 275.9M | 208.1M | 147.8M |
| Operating Income (EBIT) | (389.1M) | (333.4M) | (275.9M) | (208.1M) | (147.8M) |
| Non-Operating | |||||
| Interest Income | 24.4M | 14.7M | 18.1M | 13.1M | 4.0M |
| Interest Expense | 5.2M | 3.1M | — | — | 4.0M |
| Net Interest Income | 19.3M | 11.6M | 18.1M | 13.1M | — |
| Other Non-Op Income/Expense | 11.9M | 4.4M | 20.1M | 15.7M | 7.6M |
| Non-Operating Income (excl Interest) | (12.6M) | (7.5M) | (20.1M) | (15.7M) | (11.6M) |
| EBT (Pre-Tax Income) | (377.2M) | (328.9M) | (255.9M) | (192.4M) | (140.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (377.2M) | (328.9M) | (255.9M) | (192.4M) | (140.2M) |
| Earnings from Cont. Ops | (377.2M) | (328.9M) | (255.9M) | (192.4M) | (140.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (389.7M) | (328.9M) | (255.9M) | (192.4M) | (140.2M) |
| Per Share | |||||
| Basic EPS | ($2.31) | ($2.04) | ($2.32) | ($2.42) | ($2.26) |
| Diluted EPS | ($2.31) | ($2.04) | ($2.32) | ($2.42) | ($2.26) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 171.0M | 161.0M | 110.5M | 79.7M | 58.7M |
| Diluted Shares Outstanding | 171.0M | 161.0M | 110.5M | 79.7M | 58.7M |
| Profitability Metrics | |||||
| EBITDA | (372.9M) | (321.3M) | (251.5M) | (188.8M) | (130.4M) |
| D&A | 3.7M | 4.6M | 4.4M | 3.6M | 5.9M |
| EBIT | (376.5M) | (325.9M) | (255.9M) | (192.4M) | (136.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026